Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $173,989 | $220,835 | $39,651 | $160,668 |
| - Cash | $21,081 | $34,588 | $32,915 | $23,316 |
| + Debt | $46,873 | $46,592 | $6,778 | $3,371 |
| Enterprise Value | $199,781 | $232,839 | $13,514 | $140,723 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1,294 | -$1,177 | -$1,052 |
| % Margin | – | – | – | – |
| EBITDA | -$104,030 | -$74,812 | -$65,884 | -$55,972 |
| % Margin | – | – | – | – |
| Net Income | -$102,024 | -$71,169 | -$65,447 | -$56,413 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.62 | -1.37 | -1.73 | -2.39 |
| % Growth | -18.2% | 20.8% | 27.6% | – |
| Operating Cash Flow | -$91,907 | -$70,675 | -$57,761 | -$48,153 |
| Capital Expenditures | -$62 | -$298 | -$410 | -$397 |
| Free Cash Flow | -$91,969 | -$70,973 | -$58,171 | -$48,550 |